4.6 Review

Seven Solutions for Neuroprotection in Parkinson's Disease

Journal

MOVEMENT DISORDERS
Volume 36, Issue 2, Pages 306-316

Publisher

WILEY
DOI: 10.1002/mds.28379

Keywords

Parkinson' s disease; drug development; preclinical studies; clinical trial; neuroprotection; disease‐ modifying effect

Ask authors/readers for more resources

In the development of neuroprotective drugs for Parkinson's disease (PD), it is important to target specific patients, combine multiple treatments, establish early interventions and improve biomarkers, customize drugs, prioritize repurposed drugs, and adapt preclinical models with translational biomarkers.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. (c) 2020 International Parkinson and Movement Disorder Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available